Evidence map›Paper›PMID 29164924›Full record

ReviewThe British journal of radiology2018

Towards enhanced PET quantification in clinical oncology.

Habib Zaidi, Nicolas Karakatsanis

Open access · greenAbstract readReview
In one paragraph

Review in The British journal of radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 132 citations in OpenAlex.

  1. Article
  2. Large axial field of view PET/CT - Not just a longer PET gantry.Zeitschrift fur medizinische Physik · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Optimizing Attenuation Correction inDiagnostics (Basel, Switzerland) · 2025
    Article
  11. Article
  12. Article
  13. Robust vs. Non-robust radiomic features: the quest for optimal machine learning models using phantom and clinical studies.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  14. Distinguishing benign from malignant lesions with high [European journal of nuclear medicine and molecular imaging · 2025
    Article
  15. Self-supervised neural network for Patlak-based parametric imaging in dynamic [European journal of nuclear medicine and molecular imaging · 2025
    Article
  16. Validating image-derived input functions of dynamicFrontiers in nuclear medicine · 2025
    Article
  17. Article
  18. Deep-learning-based Attenuation Correction forMolecular imaging and radionuclide therapy · 2024
    Article
  19. Application of Dynamic [Molecular imaging and biology · 2024
    Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 4 countries.

Habib Zaidi1 Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital , Geneva , Switzerland.
Nicolas Karakatsanis5 Division of Radiopharmaceutical Sciences, Department of Radiology, Weill Cornell Medical College of Cornell Univercity , New york, NY , USA.
University of Geneva · CHUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Positron emission tomography (PET) has, since its inception, established itself as the imaging modality of choice for the in vivo quantitative assessment of molecular targets in a wide range of biochemical processes underlying tumour physiology. PET image quantification enables to ascertain a direct link between the time-varying activity concentration in organs/tissues and the fundamental parameters portraying the biological processes at the cellular level being assessed. However, the quantitative potential of PET may be affected by a number of factors related to physical effects, hardware and software system specifications, tracer kinetics, motion, scan protocol design and limitations in current image-derived PET metrics. Given the relatively large number of PET metrics reported in the literature, the selection of the best metric for fulfilling a specific task in a particular application is still a matter of debate. Quantitative PET has advanced elegantly during the last two decades and is now reaching the maturity required for clinical exploitation, particularly in oncology where it has the capability to open many avenues for clinical diagnosis, assessment of response to treatment and therapy planning. Therefore, the preservation and further enhancement of the quantitative features of PET imaging is crucial to ensure that the full clinical value of PET imaging modality is utilized in clinical oncology. Recent advancements in PET technology and methodology have paved the way for faster PET acquisitions of enhanced sensitivity to support the clinical translation of highly quantitative four-dimensional (4D) parametric imaging methods in clinical oncology. In this report, we provide an overview of recent advances and future trends in quantitative PET imaging in the context of clinical oncology. The pros/cons of the various image-derived PET metrics will be discussed and the promise of novel methodologies will be highlighted.

Indexed as

Medical OncologyFluorodeoxyglucose F18HumansImage Processing, Computer-AssistedPositron-Emission TomographyRadiopharmaceuticalsWhole Body ImagingFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID29164924
PMCPMC6049841
OpenAlexW2768342898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.